SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. (SLS) from its SEC filings: 2023 revenue $0 (-100% vs the year before), free cash flow -$31.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2023) | $0 |
| Revenue growth | -100% |
| Net income | -$37.3 million |
| Free cash flow | -$31.4 million |
| Diluted EPS | $-1.34 |
| Cash | $138.3 million |
| Long-term debt | $0 |
| Share count, 1 year | +92% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.